SpyGlass Pharma, Inc.

SGP

Explore Our Financial Data > Companies > SpyGlass Pharma, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	SGP
CIK	0001778922
SIC	3841
Sector	Manufacturing
Industry Category	Medical Equipment
Industry Group	Surgical, Medical, And Dental Instruments And Supplies

Contact

Address	27081 ALISO CREEK ROAD, SUITE 125, ALISO VIEJO, CA, 92656
Website	www.spyglasspharma.com
Phone	949-284-6904
CEO	Patrick Mooney
Employees	65

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$0.00
Pre-Tax Income	$-39.87 million
Net Income	$-39.87 million
Net Income to Common	$-39.87 million
EPS	$-17.98

View All

Balance Sheet

Cash	$96.36 million
Assets	$115.87 million
Liabilities	$10.17 million
Common Equity	$-98.84 million
Liabilities & Equity	$115.87 million

View All

Cash Flow Statement

Net Income	$-39.87 million
Cash From Operating Activities	$-32.70 million
Cash From Investing Activities	$-11.79 million
Cash From Financing Activities	$124.58 million
Change in Cash	$80.09 million

View All

Calculations

NOPAT	$-29.01 million
EBITDA	$-42.36 million
Price to Earnings	N/A
Price to Book	N/A
ROE	N/A

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update

Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) that demonstrated sustained intraocular pressure (IOP) control, elimination of IOP-lowering eye drops for 97% of trial participants, and improved visual performance, with a favorable safety profile.Phase 3 trials of BIM-IOL System are ongoing, with enrollment underwa

Article Link

SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System

97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating high quality of vision, performance in line with the state-of-the-art IOLs in the control groupOverall safety results were comparable to routine cataract surgery ALISO VIEJO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-s

Article Link

SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit

ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced that members of the executive management team will host 1x1 meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026. About SpyGlass Pharma SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye

Article Link

MongoDB downgraded, Block upgraded: Wall Street's top analyst calls

Article Link

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Block, CrowdStrike, Fortinet, MongoDB, Mosaic, Palo Alto Networks, Unity Software, and More

Pre-Market Stock Futures: Futures are down big as oil shoots higher on Tuesday. After a big early morning sell-off on Monday, the buy-the-dip buyers returned with a vengeance, and by the end of the Monday session, all of the major indices had recovered from the early heavy selling. The Dow Jones Industrial Average, which was ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Block, CrowdStrike, Fortinet, MongoDB, Mosaic, Palo Alto Networks, Unity Software, and More

Article Link